U.S. markets closed

Predictive Oncology Inc. (S1K2.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.3070+0.0120 (+4.07%)
At close: 06:45PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2950
Bid0.2900 x N/A
Ask0.3015 x N/A
Day's Range0.2949 - 0.3070
52 Week Range0.2305 - 0.9650
Avg. Volume0
Market Cap24.637M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.2920
Earnings DateNov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for S1K2.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Predictive Oncology Reports Third Quarter Financial Results

      EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights from the quarter include: Raymond F. Vennare, has been appointed as Chief Executive Officer and Chairman of the Board. An accomplished executive with more than three decades of experience, Mr. Vennare has

    • GlobeNewswire

      David S. Smith appointed to the Board of Directors of Predictive Oncology

      Leading authority on the therapeutic use of human tissues and cells Director, Predictive Oncology Inc. David S. Smith, JD EAGAN, Minn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of David S. Smith, JD, to the company’s Board of Directors. Mr. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells. He has

    • American City Business Journals

      AI cancer-therapy firm Predictive Oncology names experienced biotech exec as its next CEO

      Eagan-based Predictive Oncology, a company that uses AI to enable the development of cancer therapies, has named a new CEO.